Stavudine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
AIDS Dementia Complex
Conditions
AIDS Dementia Complex, HIV Infections
Trial Timeline
Oct 1, 1997 → Mar 1, 1999
NCT ID
NCT00002246About Stavudine
Stavudine is a phase 3 stage product being developed by Bristol Myers Squibb for AIDS Dementia Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT00002246. Target conditions include AIDS Dementia Complex, HIV Infections.
What happened to similar drugs?
4 of 10 similar drugs in AIDS Dementia Complex were approved
Approved (4) Terminated (1) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002308 | Pre-clinical | Completed |
| NCT00000988 | Phase 1 | Completed |
| NCT00000686 | Phase 1 | Terminated |
| NCT00235222 | Approved | UNKNOWN |
| NCT00002246 | Phase 3 | Completed |
| NCT00002349 | Pre-clinical | Completed |
Competing Products
20 competing products in AIDS Dementia Complex